
XORTX Therapeutics (NASDAQ:XRTX) shares are trading higher by 54.6% at $1.87 after the company announced the submission of a Patent Cooperation Treaty patent application seeking international patent protection for the patent entitled "Compositions and Methods for Enhancing Anti-Vi".
XORTX Therapeutics says the patent is based on retrospective clinical data from XORTX scientific partners suggesting that an important therapeutic opportunity lies with addressing aberrant purine metabolism combined with hyperuricemia in patients most at risk to severe COVID-19 outcome.